A balanced account
VikingGenetics’ 2023 annual report, released today, shows a net profit of EUR 658 thousand, supported by a focus on a new value pricing model, extensive changes in key markets, and continued investment in climate-oriented research.
VikingGenetics’ annual report for 2023 shows a balanced account within budget expectations, satisfying the aims in a transition year for the company’s new leadership in its first full calendar year.
A decrease in total doses sold was partly mitigated by increased demand for sexed-sorted doses and a new value pricing model on both conventional and sexed semen doses. This translated into a revenue increase from EUR 34.7 million in 2022 to EUR 35.3 million in 2023.
“We are confident that the path we are following is the right one for the value and quality of our genetics. Our mission is to create more value for Nordic farmers through innovative breeding work and continuous investment in research and development,” says Louise Helmer, CEO of VikingGenetics.